252 related articles for article (PubMed ID: 11435427)
1. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor.
Taggart CC; Lowe GJ; Greene CM; Mulgrew AT; O'Neill SJ; Levine RL; McElvaney NG
J Biol Chem; 2001 Sep; 276(36):33345-52. PubMed ID: 11435427
[TBL] [Abstract][Full Text] [Related]
2. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.
Vogelmeier C; Hubbard RC; Fells GA; Schnebli HP; Thompson RC; Fritz H; Crystal RG
J Clin Invest; 1991 Feb; 87(2):482-8. PubMed ID: 1671391
[TBL] [Abstract][Full Text] [Related]
3. Identification, origins and the diurnal role of the principal serine protease inhibitors in human tear fluid.
Sathe S; Sakata M; Beaton AR; Sack RA
Curr Eye Res; 1998 Apr; 17(4):348-62. PubMed ID: 9561826
[TBL] [Abstract][Full Text] [Related]
4. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.
Weldon S; McNally P; McElvaney NG; Elborn JS; McAuley DF; Wartelle J; Belaaouaj A; Levine RL; Taggart CC
J Immunol; 2009 Dec; 183(12):8148-56. PubMed ID: 20007580
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.
McNeely TB; Shugars DC; Rosendahl M; Tucker C; Eisenberg SP; Wahl SM
Blood; 1997 Aug; 90(3):1141-9. PubMed ID: 9242546
[TBL] [Abstract][Full Text] [Related]
6. Secretory leukocyte protease inhibitor and its potential interactions with elastase and cathepsin B in gingival crevicular fluid and saliva from patients with chronic periodontitis.
Cox SW; Rodriguez-Gonzalez EM; Booth V; Eley BM
J Periodontal Res; 2006 Oct; 41(5):477-85. PubMed ID: 16953825
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin L inactivates alpha 1-proteinase inhibitor by cleavage in the reactive site region.
Johnson DA; Barrett AJ; Mason RW
J Biol Chem; 1986 Nov; 261(31):14748-51. PubMed ID: 3490478
[TBL] [Abstract][Full Text] [Related]
8. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase.
van Wetering S; van der Linden AC; van Sterkenburg MA; Rabe KF; Schalkwijk J; Hiemstra PS
J Investig Med; 2000 Sep; 48(5):359-66. PubMed ID: 10979241
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor.
Wright CD; Kennedy JA; Zitnik RJ; Kashem MA
Biochem Biophys Res Commun; 1999 Jan; 254(3):614-7. PubMed ID: 9920787
[TBL] [Abstract][Full Text] [Related]
10. Interaction of secretory leukocyte protease inhibitor with proteinase-3.
Rao NV; Marshall BC; Gray BH; Hoidal JR
Am J Respir Cell Mol Biol; 1993 Jun; 8(6):612-6. PubMed ID: 8100709
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin processing by thyroidal proteases. Major sites of cleavage by cathepsins B, D, and L.
Dunn AD; Crutchfield HE; Dunn JT
J Biol Chem; 1991 Oct; 266(30):20198-204. PubMed ID: 1939080
[TBL] [Abstract][Full Text] [Related]
12. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination.
Taggart CC; Greene CM; McElvaney NG; O'Neill S
J Biol Chem; 2002 Sep; 277(37):33648-53. PubMed ID: 12084717
[TBL] [Abstract][Full Text] [Related]
13. Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing.
Dahl SW; Halkier T; Lauritzen C; Dolenc I; Pedersen J; Turk V; Turk B
Biochemistry; 2001 Feb; 40(6):1671-8. PubMed ID: 11327826
[TBL] [Abstract][Full Text] [Related]
14. Probing the specificity of cysteine proteinases at subsites remote from the active site: analysis of P4, P3, P2' and P3' variations in extended substrates.
Portaro FC; Santos AB; Cezari MH; Juliano MA; Juliano L; Carmona E
Biochem J; 2000 Apr; 347 Pt 1(Pt 1):123-9. PubMed ID: 10727410
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema.
Abboud RT; Vimalanathan S
Int J Tuberc Lung Dis; 2008 Apr; 12(4):361-7. PubMed ID: 18371259
[TBL] [Abstract][Full Text] [Related]
16. Distinct properties of prohormone thiol protease (PTP) compared to cathepsins B, L, and H: evidence for PTP as a novel cysteine protease.
Azaryan AV; Hook VY
Arch Biochem Biophys; 1994 Oct; 314(1):171-7. PubMed ID: 7944391
[TBL] [Abstract][Full Text] [Related]
17. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema.
Takeyabu K; Betsuyaku T; Nishimura M; Yoshioka A; Tanino M; Miyamoto K; Kawakami Y
Eur Respir J; 1998 Nov; 12(5):1033-9. PubMed ID: 9863993
[TBL] [Abstract][Full Text] [Related]
18. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.
Zani ML; Baranger K; Guyot N; Dallet-Choisy S; Moreau T
Protein Sci; 2009 Mar; 18(3):579-94. PubMed ID: 19241385
[TBL] [Abstract][Full Text] [Related]
19. Secretory leukocyte proteinase inhibitor, alpha-1-antitrypsin deficiency and emphysema: Preliminary study, speculation and an hypothesis.
Ayad MS; Knight KR; Burdon JG; Brenton S
Respirology; 2003 Jun; 8(2):175-80. PubMed ID: 12753532
[TBL] [Abstract][Full Text] [Related]
20. Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defense.
Birrer P; McElvaney NG; Gillissen A; Hoyt RF; Bloedow DC; Hubbard RC; Crystal RG
J Appl Physiol (1985); 1992 Jul; 73(1):317-23. PubMed ID: 1354669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
